🔗 Share this article

Given that the US continues making historic adjustments to its vaccine schedules, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about Covid vaccinations during the global health crisis and has focused upon possible fatalities after Covid immunization in her brief time at the FDA.

Proposed Shifts to Pediatric Vaccine Schedule

Health officials were set to unveil sweeping changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would place the US out of step with a large portion of the international standard with little proof for benefit. The planned update has been pushed back until the next year.

Rather than Vinay Prasad, Høeg is listed to present at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

Consolidating Power at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for discontinuing specific childhood vaccine recommendations in the US to become more in line with Denmark, a society with nationalized medicine and a population about the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Expertise

Høeg has no apparent background in medication creation, approval processes or administrative roles, which has been customary for past heads of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She is not an expert in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an enormous workload at the FDA, she emphasized.

“The public just zeroes in on the innovative therapies, but the generic program authorizes numerous generic drugs. There is also a biosimilars program, over-the-counter program and more, and every single one need to be managed,” Woodcock explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the position, which supervises in excess of 5,000 employees. “It is a enormous leadership role, if you execute it properly,” she said.

Official Statement and Controversial Initiatives

In response to questions about Høeg’s qualifications and whether this appointment represents increased cooperation among agency officials on immunizations, a representative said that the “inquiries are based on flawed assumptions”.

“This background is consistent with the duties of her role,” the representative stated, pointing to the months Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial rapid medication authorization process that reportedly troubled her former heads. “How are these therapies being selected for this fast-track system? Who makes the decisions?” Howard asked. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent rules of all drugs, with the exception of shots.”

Public History on Immunizations

With immunizations, Høeg has a more documented, if concerning, past, critics said. She published a analysis using unconfirmed volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming government encompassed revising regulations for novel immunizations and ending “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has allegedly suggested barring adolescent males from obtaining Covid vaccines.

“She is an complete dogmatist who commences with her preconceived notions and reverse-engineers to fit the evidence in a highly disingenuous, dishonest way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|